ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS

Michael Brownlee, Anthony Cerami, Jenny J. Li, Helen Vlassara, Terry R. Martin, Keith P.W.J. Mcadam

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Serum concentrations of serum amyloid A protein, the high-density-lipoprotein-associated tissue amyloid A precursor, were determined in 29 diabetic patients receiving insulin by subcutaneous injection and in 50 receiving subcutaneous infusion pump therapy. Insulin delivered by continuous subcutaneous pumps stimulated serum amyloid A production to levels nearly six times those in normal subjects, nearly twice as much as insulin given by subcutaneous injection. 85% of patients with serum amyloid A levels {succeeds or equal to}104 ng/ml were being treated with insulin pump therapy. The relation between insulin aggregation and amyloid A in diabetes was evaluated in 1 patient; treatment with syringe-aggregated insulin resulted in a nearly 300% increase in serum amyloid A levels. The use of high-potency non-aggregating insulins in the pump treatment of type I diabetic patients may be necessary for optimum therapy.

Original languageEnglish (US)
Pages (from-to)411-413
Number of pages3
JournalThe Lancet
Volume323
Issue number8374
DOIs
Publication statusPublished - Feb 25 1984

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brownlee, M., Cerami, A., Li, J. J., Vlassara, H., Martin, T. R., & Mcadam, K. P. W. J. (1984). ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS. The Lancet, 323(8374), 411-413. https://doi.org/10.1016/S0140-6736(84)91750-1